PART I . Overview We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Our portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. ARCALYST is an interleukin-1 (IL-1) and interleukin-1 (IL-1) cytokine trap. In 2017, we licensed ARCALYST from Regeneron, which discovered and initially developed the drug. Our exclusive license...
Q2 FY2026 — expected 2026-09-17
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | KNSA | discussed_in_filing Cybersecurity | |
| topic_mention | KNSA | discussed_in_filing Trusted Computing | |
| topic_mention | KNSA | discussed_in_filing Blockchain & Crypto | |
| topic_mention | KNSA | discussed_in_filing Capital Expenditure | |
| topic_mention | KNSA | discussed_in_filing Supply Chain | |
| topic_mention | KNSA | discussed_in_filing Regulation | |
| topic_mention | KNSA | discussed_in_filing Healthcare & Bio | |
| topic_mention | KNSA | discussed_in_filing Sovereign & Government | |
| topic_mention | KNSA | discussed_in_filing Cybersecurity | |
| topic_mention | KNSA | discussed_in_filing Trusted Computing | |
| topic_mention | KNSA | discussed_in_filing Blockchain & Crypto | |
| topic_mention | KNSA | discussed_in_filing Capital Expenditure | |
| topic_mention | KNSA | discussed_in_filing Supply Chain | |
| topic_mention | KNSA | discussed_in_filing Regulation | |
| topic_mention | KNSA | discussed_in_filing Healthcare & Bio | |
| topic_mention | KNSA | discussed_in_filing Sovereign & Government | |
| topic_mention | KNSA | discussed_in_filing Cybersecurity | |
| topic_mention | KNSA | discussed_in_filing Trusted Computing | |
| topic_mention | KNSA | discussed_in_filing Blockchain & Crypto | |
| topic_mention | KNSA | discussed_in_filing Capital Expenditure |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001104659-26-019168 | EDGAR | 104K words |
| 2025-02-25 | 2024-12-31 | 0001558370-25-001505 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0001558370-24-002005 | EDGAR | — |
| 2023-03-02 | 2022-12-31 | 0001558370-23-002684 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001558370-22-001932 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001558370-21-001821 | EDGAR | — |
| 2020-03-05 | 2019-12-31 | 0001558370-20-002081 | EDGAR | — |
| 2019-03-12 | 2018-12-31 | 0001558370-19-001857 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-28 | 2025-09-30 | 0001104659-25-103180 | EDGAR | 71K words |
| 2025-07-29 | 2025-06-30 | 0001558370-25-009738 | EDGAR | — |
| 2025-04-29 | 2025-03-31 | 0001558370-25-005847 | EDGAR | — |
| 2024-10-29 | 2024-09-30 | 0001558370-24-013840 | EDGAR | — |
| 2024-07-25 | 2024-06-30 | 0001558370-24-010181 | EDGAR | — |
| 2024-04-25 | 2024-03-31 | 0001558370-24-005774 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001558370-23-017423 | EDGAR | — |
| 2023-08-01 | 2023-06-30 | 0001558370-23-012729 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001558370-23-008113 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001558370-22-016250 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001558370-22-012203 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001558370-22-007381 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-24 | 0001730430-26-000014 | EDGAR | 3K words |
| 2026-01-14 | 0001730430-26-000010 | EDGAR | — |
| 2026-01-12 | 0001730430-26-000005 | EDGAR | — |
| 2025-10-28 | 0001104659-25-102834 | EDGAR | — |
| 2025-09-03 | 0001104659-25-086689 | EDGAR | — |
| 2025-07-29 | 0001104659-25-071413 | EDGAR | — |
| 2025-06-05 | 0001104659-25-056665 | EDGAR | — |
| 2025-06-03 | 0001104659-25-055990 | EDGAR | — |
| 2025-04-29 | 0001104659-25-040641 | EDGAR | — |
| 2025-04-23 | 0001104659-25-038041 | EDGAR | — |
129 total filings indexed. 99 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001730430 |
| Ticker | KNSA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report